Wakix
-
Plymouth Meeting Pharmaceutical Company Eyes $1B Milestone
Harmony Biosciences says its flagship narcolepsy drug is on track to hit a major milestone, writes John George for The…
-
Flagship Drug Sales Boost Plymouth Meeting-Based Harmony Biosciences Stock
Plymouth Meeting-based Harmony Biosciences saw its stock rise by almost 13 percent Thursday after reporting positive sales growth for Wakix,…
-
Plymouth Meeting’s Harmony Biosciences Pivots After FDA Rejects Wakix for Sleep Disorder
Plymouth Meeting’s Harmony Biosciences’ stock fell 10% on Wednesday after the FDA rejected the expansion of its insomnia drug, Wakix,…
-
Harmony Biosciences in Plymouth Meeting OK’d for Sleep Disorder Drug Use
Plymouth Meeting-based Harmony Biosciences received a green light from the Food and Drug Administration to widen the use of Wakix,…
-
Plymouth Meeting-Based Harmony Biosciences Seeks FDA Nod for Pediatric Use of Narcolepsy Drug Wakix
The Food and Drug Administration (FDA) is set to decide by Thursday on Plymouth Meeting-based Harmony Biosciences‘ application to expand…
-
Plymouth Meeting-based Harmony Biosciences Enters Exclusive Licensing Deal for Potential New Narcolepsy Therapy
Harmony Biosciences, a Plymouth Meeting-based pharmaceutical company, has entered into an exclusive licensing deal for the rights to develop and…
-
Plymouth Meeting Biotech Firm Stock Soars Following IPO
Shares of Plymouth Meeting-based Harmony Biosciences Holdings soared as much as 70 percent over the public offering price on the…
-
Harmony Biosciences Looking to Raise $100 Million in IPO to Study Key Ingredient in Wakix
Plymouth Meeting-based Harmony Biosciences, which markets the drug Wakix for patients with narcolepsy, is planning to raise $100 million with…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
